Richard W Joseph Jr. MD

Oncology•Jacksonville, FL

Genitourinary Oncology, Hematologic Oncology, Melanoma

Senior Medical Director Daiichi Sankyo

Join to View Full Profile

4500 San Pablo Rd SJacksonville, FL 32224
Phone+1 904-953-2000
Fax+1 888-978-4098

Summary

I am a medical oncologist working in Drug Development for Daiichi Sankyo.

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2004 - 2007
Emory University School of MedicineClass of 2004

Certifications & Licensure

NY State Medical License 2006 - Present
FL State Medical License 2011 - 2027
TX State Medical License 2007 - 2011
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

AACR Career Development Award AACR, 2012
ASCO Young Investigator Award ASCO, 2009

Clinical Trials

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma Start of enrollment: 2014 Jan 08
Completed
Phase 2
Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)
No longer available
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2) Start of enrollment: 2014 May 31
Completed
Phase 2

Publications & Presentations

PubMed

24 citations
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carc...
Thomas Powles, Michael B. Atkins, Bernard Escudier, Robert J. Motzer, Brian I. Rini
European Urology. 2021-05-01
4 citations
Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial.
Patricia LoRusso, Aleksandar Sekulic, Jeffrey A. Sosman, Winnie S. Liang, John D. Carpten
Plos One. 2021-04-07
45 citations
A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma
Irbaz Bin Riaz, Huan He, Alexander J. Ryu, Rabbia Siddiqi, Syed Arsalan Ahmed Naqvi
European Urology. 2021-04-03

Journal Articles

Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...
Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Carcinoma
Michael B Atkins, Thomas Hutson, Mario Sznol, Toni K Choueiri, Sumanta K Pal, Richard W Joseph, John Hainsworth, W Kimryn Rathmell, David F McDermott, Robert J Motzer,..., Nature

Lectures

Health-related quality of life (HRQoL) in patients with advanced melanoma receiving immunotherapies across real-world clinical practice settings.
2019 ASCO Annual Meeting - 6/1/2019
Health care resource utilization in patients with advanced melanoma receiving immunotherapies in the real world.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Pembrolizumab May Help Prevent Early-Stage Melanoma from ReturningOctober 13th, 2021
Presents State of the Science Summit™ on Genitourinary CancersJuly 23rd, 2019
Immunotherapy Highly Effective in Treatment of Rare Skin Cancer, Study FindsJanuary 10th, 2018
Join now to see all

Professional Memberships